The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 1
From BugSigDB
Needs review
Subjects
- Location of subjects
- Austria
- United Kingdom
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to drug drug resistance,drug susceptibility/resistance,Response to drug,response to drug
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Loxapine Succinate High (LOX-High), Loxapine Succinate Low(LOX-Low) and Entacapone Low(ENT-Low) after 24hours of incubation
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Entacapone High Concentration(ENT-High) after 24 hrs of incubation
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Entacapone High Concentration(ENT-High) after 24hrs of incubation, refers to the drug concentration given to the six healthy adult individuals after twenty-four hours of incubation. Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that acts by preventing the degradation of levodopa. It is the main drug used in the treatment of Parkinson’s disease. High concentration was based on estimated colon concentration and was included to better reflect the exposure of gut microbes to drugs in the large intestine.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 9
- Group 1 sample size Number of subjects in the case (exposed) group
- 3
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- raw counts
- Statistical test
- DESeq2
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Needs review
Source: Supplementary Table 5
Description: Differential abundance of taxa between the drug-amendment experiments(ENT-High, ENT-Low, LOX-High and LOX-Low) after 24hrs of incubation.
Abundance in Group 1: increased abundance in Entacapone High Concentration(ENT-High) after 24 hrs of incubation
Revision editor(s): KateRasheed
Signature 2
Needs review
Source: Supplementary Table 5
Description: Differential abundance of taxa between the drug-amendment experiments(ENT-High, ENT-Low, LOX-High and LOX-Low) after 24hrs of incubation.
Abundance in Group 1: decreased abundance in Entacapone High Concentration(ENT-High) after 24 hrs of incubation
Revision editor(s): KateRasheed
